Global Traumatic Brain Injury Therapeutics research
Global Traumatic Brain Injury Therapeutics research

Traumatic Brain Injury Therapeutics Comprehensive Study by Type (Immediate emergency care, Medications (Diuretics, Anti-seizure drugs, Coma-inducing drugs, Anti-anxiety agents, Antidepressants, Anti-psychotics, Analgesic, Anti-convulsant, Anti-coagulants, Surgery (Removing clotted blood (hematomas), Repairing skull fractures, Bleeding in the brain, Opening a window in the skull, Rehabilitation)), Application (Focal TBI, Open TBI, Closed TBI, Diffuse TBI, Primary TBI, Others), End User (Hospitals, Neurologist, Independent pharmacies, Rehabilitative center treatment, Other) Players and Region - Global Market Outlook to 2027

Traumatic Brain Injury Therapeutics Market Segmented into XX Submarkets. | Forecast Years: 2022- 2027  

Mar 2022 Edition 240 Pages 72 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is Traumatic Brain Injury Therapeutics Market Scope?
TBI, or traumatic brain injury, is caused by severe or little damage to the brain tissue caused by accidents or assaults. TBI affects roughly 1.7 million persons in North America each year, with medical expenses exceeding USD 70 billion. TBI affects nearly 10 million individuals worldwide each year, according to the World Health Organization. Because brain tissue has one of the lowest capacities for self-repair, it is extremely vulnerable to injuries, often resulting in permanent loss or handicap of motor functions, which drastically lowers one's quality of life. The majority of neuronal damage happens after the event, allowing for therapeutic intervention. Due to their negative consequences, the earlier intervention with glucocorticoids is not considered. Traumatic brain injury therapies are one of the many therapeutic approaches accessible in the healthcare business for the treatment of varying degrees of traumatic brain injuries. The majority of the treatment consists of modest medications meant to treat lower-grade injuries.

The Traumatic Brain Injury Therapeutics market study is being classified by Type (Immediate emergency care, Medications [Diuretics, Anti-seizure drugs, Coma-inducing drugs, Anti-anxiety agents, Antidepressants, Anti-psychotics, Analgesic, Anti-convulsant, Anti-coagulants and Surgery [Removing clotted blood (hematomas), Repairing skull fractures, Bleeding in the brain, Opening a window in the skull, Rehabilitation]), by Application (Focal TBI, Open TBI, Closed TBI, Diffuse TBI, Primary TBI and Others) and major geographies with country level break-up.

The competitive landscape for traumatic brain injury therapy includes information from competitors. Company overview, financials, revenue generated, market potential, investment in R&D, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, and application dominance are among the details included. Analysts at AMA predicts that Players from United States will contribute to the maximum growth of Global Traumatic Brain Injury Therapeutics market throughout the predicted period.

Teva Pharmaceutical Industries Ltd. (Isreal), Sanofi (France), Novartis AG (Switzerland), Pfizer Inc. (United States), Akorn Pharmaceuticals (United States), Arbor Pharmaceuticals (United States), F. Hoffmann-La Roche Ltd.(Switzerland), Invagen pharms (India), Apotex Inc. (Canada) and Mylan N.V. (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Neuren Pharmaceuticals Ltd. (Australia), Oxygen Biotherapeutics Inc. (United States) and Avanir Pharmaceuticals Inc. (United States).

Segmentation Analysis
Analyst at AMA have segmented the market study of Global Traumatic Brain Injury Therapeutics market by Type, Application and Region.

On the basis of geography, the market of Traumatic Brain Injury Therapeutics has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). North America region held largest market share in the year 2021. Europe on the other hand stood as second largest market due to the presence of key companies into the region and high technological advancement.

Market Influencers and their development strategies
On 26th October 2021, Teva Pharmaceutical Industries Ltd. and MODAG GmbH today announced a strategic collaboration on the exclusive worldwide licensing and development of MODAG's lead compound anle138b and a related compound, sery433.



Influencing Market Trend
  • Sports-related car accidents and injuries are on the rise.
  • A growing number of research are in the works to find novel TBI treatments.

Market Drivers
  • The therapy and repair of this condition necessitate extensive surgical operations.
  • The government's expanding efforts to discover novel TBI treatment solutions

Opportunities
  • Growing Demand for various technological developments and advancements
  • Increasing the scope of significant research and development
  • Clinical trials for the development of traumatic brain injuries are being undertaken in large numbers.

Restraints
  • The lack of awareness of this treatment among diverse groups and consumers in developing economies
  • The government's strict and severe system of rules and regulations

Challenges
  • The delayed diagnosis of TBI may hinder the traumatic brain injury therapeutics market


Key Target Audience
Traumatic Brain Injury Therapeutics Providers, Government Regulatory Bodies, Private Research Orgnization, Government Research Orgnization and Others

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.

To compete effectively, companies also require quantitative estimates of the future growth and qualitative nature of the market. AMA Research features not just specific market sizing estimates, but also include significant value-added commentary on Technological Trends and Innovations, Regulatory Policies, Market Maturity Indicators, Market Share Movements, New Entrants into the Market & Entry/Exit Barriers, Consumer Demographics, Supporting Company Financial and Cash Flow Planning, Open Up New Markets , To Seize Powerful Market Opportunities, Key Decision in Planning and to Further Expand Market Share, Identify Key Business Segments, Market Proposition & Gap Analysis.

Frequently Asked Questions (FAQ):

1. At what growth rate would the Traumatic Brain Injury Therapeutics market expands?
The Global Traumatic Brain Injury Therapeutics market is expected to see a growth of % during projected year 2021 to 2027.

2. Who are the prominent players of the Global Traumatic Brain Injury Therapeutics market?
The prominent players of Global Traumatic Brain Injury Therapeutics market are Teva Pharmaceutical Industries Ltd. (Isreal), Sanofi (France), Novartis AG (Switzerland), Pfizer Inc. (United States), Akorn Pharmaceuticals (United States), Arbor Pharmaceuticals (United States), F. Hoffmann-La Roche Ltd.(Switzerland), Invagen pharms (India), Apotex Inc. (Canada) and Mylan N.V. (United States), to name a few.

3. What are the top priorities to focus for Traumatic Brain Injury Therapeutics marketís growth?
In this highly competitive & fast evolving Traumatic Brain Injury Therapeutics industry, the top strategic priorities would remain consistent like innovation, R&D and M&A.
Report Objectives / Segmentation Covered
By Type
  • Immediate emergency care
  • Medications [Diuretics, Anti-seizure drugs, Coma-inducing drugs, Anti-anxiety agents, Antidepressants, Anti-psychotics, Analgesic, Anti-convulsant, Anti-coagulants
  • Surgery [Removing clotted blood (hematomas), Repairing skull fractures, Bleeding in the brain, Opening a window in the skull, Rehabilitation]
By Application
  • Focal TBI
  • Open TBI
  • Closed TBI
  • Diffuse TBI
  • Primary TBI
  • Others
By End User
  • Hospitals
  • Neurologist
  • Independent pharmacies
  • Rehabilitative center treatment
  • Other

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. The therapy and repair of this condition necessitate extensive surgical operations.
      • 3.2.2. The government's expanding efforts to discover novel TBI treatment solutions
    • 3.3. Market Challenges
      • 3.3.1. The delayed diagnosis of TBI may hinder the traumatic brain injury therapeutics market
    • 3.4. Market Trends
      • 3.4.1. Sports-related car accidents and injuries are on the rise.
      • 3.4.2. A growing number of research are in the works to find novel TBI treatments.
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Traumatic Brain Injury Therapeutics, by Type, Application, End User and Region (value and price ) (2016-2021)
    • 5.1. Introduction
    • 5.2. Global Traumatic Brain Injury Therapeutics (Value)
      • 5.2.1. Global Traumatic Brain Injury Therapeutics by: Type (Value)
        • 5.2.1.1. Immediate emergency care
        • 5.2.1.2. Medications [Diuretics, Anti-seizure drugs, Coma-inducing drugs, Anti-anxiety agents, Antidepressants, Anti-psychotics, Analgesic, Anti-convulsant, Anti-coagulants
        • 5.2.1.3. Surgery [Removing clotted blood (hematomas), Repairing skull fractures, Bleeding in the brain, Opening a window in the skull, Rehabilitation]
      • 5.2.2. Global Traumatic Brain Injury Therapeutics by: Application (Value)
        • 5.2.2.1. Focal TBI
        • 5.2.2.2. Open TBI
        • 5.2.2.3. Closed TBI
        • 5.2.2.4. Diffuse TBI
        • 5.2.2.5. Primary TBI
        • 5.2.2.6. Others
      • 5.2.3. Global Traumatic Brain Injury Therapeutics by: End User (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Neurologist
        • 5.2.3.3. Independent pharmacies
        • 5.2.3.4. Rehabilitative center treatment
        • 5.2.3.5. Other
      • 5.2.4. Global Traumatic Brain Injury Therapeutics Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global Traumatic Brain Injury Therapeutics (Price)
      • 5.3.1. Global Traumatic Brain Injury Therapeutics by: Type (Price)
  • 6. Traumatic Brain Injury Therapeutics: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2021)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Teva Pharmaceutical Industries Ltd. (Isreal)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Sanofi (France)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Akorn Pharmaceuticals (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Arbor Pharmaceuticals (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. F. Hoffmann-La Roche Ltd.(Switzerland)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Invagen pharms (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Apotex Inc. (Canada)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Mylan N.V. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Traumatic Brain Injury Therapeutics Sale, by Type, Application, End User and Region (value and price ) (2022-2027)
    • 7.1. Introduction
    • 7.2. Global Traumatic Brain Injury Therapeutics (Value)
      • 7.2.1. Global Traumatic Brain Injury Therapeutics by: Type (Value)
        • 7.2.1.1. Immediate emergency care
        • 7.2.1.2. Medications [Diuretics, Anti-seizure drugs, Coma-inducing drugs, Anti-anxiety agents, Antidepressants, Anti-psychotics, Analgesic, Anti-convulsant, Anti-coagulants
        • 7.2.1.3. Surgery [Removing clotted blood (hematomas), Repairing skull fractures, Bleeding in the brain, Opening a window in the skull, Rehabilitation]
      • 7.2.2. Global Traumatic Brain Injury Therapeutics by: Application (Value)
        • 7.2.2.1. Focal TBI
        • 7.2.2.2. Open TBI
        • 7.2.2.3. Closed TBI
        • 7.2.2.4. Diffuse TBI
        • 7.2.2.5. Primary TBI
        • 7.2.2.6. Others
      • 7.2.3. Global Traumatic Brain Injury Therapeutics by: End User (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Neurologist
        • 7.2.3.3. Independent pharmacies
        • 7.2.3.4. Rehabilitative center treatment
        • 7.2.3.5. Other
      • 7.2.4. Global Traumatic Brain Injury Therapeutics Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global Traumatic Brain Injury Therapeutics (Price)
      • 7.3.1. Global Traumatic Brain Injury Therapeutics by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Traumatic Brain Injury Therapeutics: by Type(USD Million)
  • Table 2. Traumatic Brain Injury Therapeutics Immediate emergency care , by Region USD Million (2016-2021)
  • Table 3. Traumatic Brain Injury Therapeutics Medications [Diuretics, Anti-seizure drugs, Coma-inducing drugs, Anti-anxiety agents, Antidepressants, Anti-psychotics, Analgesic, Anti-convulsant, Anti-coagulants , by Region USD Million (2016-2021)
  • Table 4. Traumatic Brain Injury Therapeutics Surgery [Removing clotted blood (hematomas), Repairing skull fractures, Bleeding in the brain, Opening a window in the skull, Rehabilitation] , by Region USD Million (2016-2021)
  • Table 5. Traumatic Brain Injury Therapeutics: by Application(USD Million)
  • Table 6. Traumatic Brain Injury Therapeutics Focal TBI , by Region USD Million (2016-2021)
  • Table 7. Traumatic Brain Injury Therapeutics Open TBI , by Region USD Million (2016-2021)
  • Table 8. Traumatic Brain Injury Therapeutics Closed TBI , by Region USD Million (2016-2021)
  • Table 9. Traumatic Brain Injury Therapeutics Diffuse TBI , by Region USD Million (2016-2021)
  • Table 10. Traumatic Brain Injury Therapeutics Primary TBI , by Region USD Million (2016-2021)
  • Table 11. Traumatic Brain Injury Therapeutics Others , by Region USD Million (2016-2021)
  • Table 12. Traumatic Brain Injury Therapeutics: by End User(USD Million)
  • Table 13. Traumatic Brain Injury Therapeutics Hospitals , by Region USD Million (2016-2021)
  • Table 14. Traumatic Brain Injury Therapeutics Neurologist , by Region USD Million (2016-2021)
  • Table 15. Traumatic Brain Injury Therapeutics Independent pharmacies , by Region USD Million (2016-2021)
  • Table 16. Traumatic Brain Injury Therapeutics Rehabilitative center treatment , by Region USD Million (2016-2021)
  • Table 17. Traumatic Brain Injury Therapeutics Other , by Region USD Million (2016-2021)
  • Table 18. South America Traumatic Brain Injury Therapeutics, by Country USD Million (2016-2021)
  • Table 19. South America Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 20. South America Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 21. South America Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 22. Brazil Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 23. Brazil Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 24. Brazil Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 25. Argentina Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 26. Argentina Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 27. Argentina Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 28. Rest of South America Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 29. Rest of South America Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 30. Rest of South America Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 31. Asia Pacific Traumatic Brain Injury Therapeutics, by Country USD Million (2016-2021)
  • Table 32. Asia Pacific Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 33. Asia Pacific Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 34. Asia Pacific Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 35. China Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 36. China Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 37. China Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 38. Japan Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 39. Japan Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 40. Japan Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 41. India Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 42. India Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 43. India Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 44. South Korea Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 45. South Korea Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 46. South Korea Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 47. Taiwan Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 48. Taiwan Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 49. Taiwan Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 50. Australia Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 51. Australia Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 52. Australia Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 53. Rest of Asia-Pacific Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 54. Rest of Asia-Pacific Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 55. Rest of Asia-Pacific Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 56. Europe Traumatic Brain Injury Therapeutics, by Country USD Million (2016-2021)
  • Table 57. Europe Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 58. Europe Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 59. Europe Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 60. Germany Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 61. Germany Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 62. Germany Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 63. France Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 64. France Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 65. France Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 66. Italy Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 67. Italy Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 68. Italy Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 69. United Kingdom Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 70. United Kingdom Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 71. United Kingdom Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 72. Netherlands Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 73. Netherlands Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 74. Netherlands Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 75. Rest of Europe Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 76. Rest of Europe Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 77. Rest of Europe Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 78. MEA Traumatic Brain Injury Therapeutics, by Country USD Million (2016-2021)
  • Table 79. MEA Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 80. MEA Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 81. MEA Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 82. Middle East Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 83. Middle East Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 84. Middle East Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 85. Africa Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 86. Africa Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 87. Africa Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 88. North America Traumatic Brain Injury Therapeutics, by Country USD Million (2016-2021)
  • Table 89. North America Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 90. North America Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 91. North America Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 92. United States Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 93. United States Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 94. United States Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 95. Canada Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 96. Canada Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 97. Canada Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 98. Mexico Traumatic Brain Injury Therapeutics, by Type USD Million (2016-2021)
  • Table 99. Mexico Traumatic Brain Injury Therapeutics, by Application USD Million (2016-2021)
  • Table 100. Mexico Traumatic Brain Injury Therapeutics, by End User USD Million (2016-2021)
  • Table 101. Traumatic Brain Injury Therapeutics: by Type(USD/Units)
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Company Basic Information, Sales Area and Its Competitors
  • Table 105. Company Basic Information, Sales Area and Its Competitors
  • Table 106. Company Basic Information, Sales Area and Its Competitors
  • Table 107. Company Basic Information, Sales Area and Its Competitors
  • Table 108. Company Basic Information, Sales Area and Its Competitors
  • Table 109. Company Basic Information, Sales Area and Its Competitors
  • Table 110. Company Basic Information, Sales Area and Its Competitors
  • Table 111. Company Basic Information, Sales Area and Its Competitors
  • Table 112. Traumatic Brain Injury Therapeutics: by Type(USD Million)
  • Table 113. Traumatic Brain Injury Therapeutics Immediate emergency care , by Region USD Million (2022-2027)
  • Table 114. Traumatic Brain Injury Therapeutics Medications [Diuretics, Anti-seizure drugs, Coma-inducing drugs, Anti-anxiety agents, Antidepressants, Anti-psychotics, Analgesic, Anti-convulsant, Anti-coagulants , by Region USD Million (2022-2027)
  • Table 115. Traumatic Brain Injury Therapeutics Surgery [Removing clotted blood (hematomas), Repairing skull fractures, Bleeding in the brain, Opening a window in the skull, Rehabilitation] , by Region USD Million (2022-2027)
  • Table 116. Traumatic Brain Injury Therapeutics: by Application(USD Million)
  • Table 117. Traumatic Brain Injury Therapeutics Focal TBI , by Region USD Million (2022-2027)
  • Table 118. Traumatic Brain Injury Therapeutics Open TBI , by Region USD Million (2022-2027)
  • Table 119. Traumatic Brain Injury Therapeutics Closed TBI , by Region USD Million (2022-2027)
  • Table 120. Traumatic Brain Injury Therapeutics Diffuse TBI , by Region USD Million (2022-2027)
  • Table 121. Traumatic Brain Injury Therapeutics Primary TBI , by Region USD Million (2022-2027)
  • Table 122. Traumatic Brain Injury Therapeutics Others , by Region USD Million (2022-2027)
  • Table 123. Traumatic Brain Injury Therapeutics: by End User(USD Million)
  • Table 124. Traumatic Brain Injury Therapeutics Hospitals , by Region USD Million (2022-2027)
  • Table 125. Traumatic Brain Injury Therapeutics Neurologist , by Region USD Million (2022-2027)
  • Table 126. Traumatic Brain Injury Therapeutics Independent pharmacies , by Region USD Million (2022-2027)
  • Table 127. Traumatic Brain Injury Therapeutics Rehabilitative center treatment , by Region USD Million (2022-2027)
  • Table 128. Traumatic Brain Injury Therapeutics Other , by Region USD Million (2022-2027)
  • Table 129. South America Traumatic Brain Injury Therapeutics, by Country USD Million (2022-2027)
  • Table 130. South America Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 131. South America Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 132. South America Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 133. Brazil Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 134. Brazil Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 135. Brazil Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 136. Argentina Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 137. Argentina Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 138. Argentina Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 139. Rest of South America Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 140. Rest of South America Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 141. Rest of South America Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 142. Asia Pacific Traumatic Brain Injury Therapeutics, by Country USD Million (2022-2027)
  • Table 143. Asia Pacific Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 144. Asia Pacific Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 145. Asia Pacific Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 146. China Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 147. China Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 148. China Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 149. Japan Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 150. Japan Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 151. Japan Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 152. India Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 153. India Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 154. India Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 155. South Korea Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 156. South Korea Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 157. South Korea Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 158. Taiwan Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 159. Taiwan Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 160. Taiwan Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 161. Australia Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 162. Australia Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 163. Australia Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 164. Rest of Asia-Pacific Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 165. Rest of Asia-Pacific Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 166. Rest of Asia-Pacific Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 167. Europe Traumatic Brain Injury Therapeutics, by Country USD Million (2022-2027)
  • Table 168. Europe Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 169. Europe Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 170. Europe Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 171. Germany Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 172. Germany Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 173. Germany Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 174. France Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 175. France Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 176. France Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 177. Italy Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 178. Italy Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 179. Italy Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 180. United Kingdom Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 181. United Kingdom Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 182. United Kingdom Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 183. Netherlands Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 184. Netherlands Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 185. Netherlands Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 186. Rest of Europe Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 187. Rest of Europe Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 188. Rest of Europe Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 189. MEA Traumatic Brain Injury Therapeutics, by Country USD Million (2022-2027)
  • Table 190. MEA Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 191. MEA Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 192. MEA Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 193. Middle East Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 194. Middle East Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 195. Middle East Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 196. Africa Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 197. Africa Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 198. Africa Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 199. North America Traumatic Brain Injury Therapeutics, by Country USD Million (2022-2027)
  • Table 200. North America Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 201. North America Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 202. North America Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 203. United States Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 204. United States Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 205. United States Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 206. Canada Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 207. Canada Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 208. Canada Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 209. Mexico Traumatic Brain Injury Therapeutics, by Type USD Million (2022-2027)
  • Table 210. Mexico Traumatic Brain Injury Therapeutics, by Application USD Million (2022-2027)
  • Table 211. Mexico Traumatic Brain Injury Therapeutics, by End User USD Million (2022-2027)
  • Table 212. Traumatic Brain Injury Therapeutics: by Type(USD/Units)
  • Table 213. Research Programs/Design for This Report
  • Table 214. Key Data Information from Secondary Sources
  • Table 215. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Traumatic Brain Injury Therapeutics: by Type USD Million (2016-2021)
  • Figure 5. Global Traumatic Brain Injury Therapeutics: by Application USD Million (2016-2021)
  • Figure 6. Global Traumatic Brain Injury Therapeutics: by End User USD Million (2016-2021)
  • Figure 7. South America Traumatic Brain Injury Therapeutics Share (%), by Country
  • Figure 8. Asia Pacific Traumatic Brain Injury Therapeutics Share (%), by Country
  • Figure 9. Europe Traumatic Brain Injury Therapeutics Share (%), by Country
  • Figure 10. MEA Traumatic Brain Injury Therapeutics Share (%), by Country
  • Figure 11. North America Traumatic Brain Injury Therapeutics Share (%), by Country
  • Figure 12. Global Traumatic Brain Injury Therapeutics: by Type USD/Units (2016-2021)
  • Figure 13. Global Traumatic Brain Injury Therapeutics share by Players 2021 (%)
  • Figure 14. Global Traumatic Brain Injury Therapeutics share by Players (Top 3) 2021(%)
  • Figure 15. Global Traumatic Brain Injury Therapeutics share by Players (Top 5) 2021(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. Teva Pharmaceutical Industries Ltd. (Isreal) Revenue, Net Income and Gross profit
  • Figure 18. Teva Pharmaceutical Industries Ltd. (Isreal) Revenue: by Geography 2021
  • Figure 19. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 20. Sanofi (France) Revenue: by Geography 2021
  • Figure 21. Novartis AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 22. Novartis AG (Switzerland) Revenue: by Geography 2021
  • Figure 23. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer Inc. (United States) Revenue: by Geography 2021
  • Figure 25. Akorn Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 26. Akorn Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 27. Arbor Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 28. Arbor Pharmaceuticals (United States) Revenue: by Geography 2021
  • Figure 29. F. Hoffmann-La Roche Ltd.(Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. F. Hoffmann-La Roche Ltd.(Switzerland) Revenue: by Geography 2021
  • Figure 31. Invagen pharms (India) Revenue, Net Income and Gross profit
  • Figure 32. Invagen pharms (India) Revenue: by Geography 2021
  • Figure 33. Apotex Inc. (Canada) Revenue, Net Income and Gross profit
  • Figure 34. Apotex Inc. (Canada) Revenue: by Geography 2021
  • Figure 35. Mylan N.V. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Mylan N.V. (United States) Revenue: by Geography 2021
  • Figure 37. Global Traumatic Brain Injury Therapeutics: by Type USD Million (2022-2027)
  • Figure 38. Global Traumatic Brain Injury Therapeutics: by Application USD Million (2022-2027)
  • Figure 39. Global Traumatic Brain Injury Therapeutics: by End User USD Million (2022-2027)
  • Figure 40. South America Traumatic Brain Injury Therapeutics Share (%), by Country
  • Figure 41. Asia Pacific Traumatic Brain Injury Therapeutics Share (%), by Country
  • Figure 42. Europe Traumatic Brain Injury Therapeutics Share (%), by Country
  • Figure 43. MEA Traumatic Brain Injury Therapeutics Share (%), by Country
  • Figure 44. North America Traumatic Brain Injury Therapeutics Share (%), by Country
  • Figure 45. Global Traumatic Brain Injury Therapeutics: by Type USD/Units (2022-2027)
Some of the key companies/manufacturers profiled in the report
  • Teva Pharmaceutical Industries Ltd. (Isreal)
  • Sanofi (France)
  • Novartis AG (Switzerland)
  • Pfizer Inc. (United States)
  • Akorn Pharmaceuticals (United States)
  • Arbor Pharmaceuticals (United States)
  • F. Hoffmann-La Roche Ltd.(Switzerland)
  • Invagen pharms (India)
  • Apotex Inc. (Canada)
  • Mylan N.V. (United States)
Additional players considered in the study are as follows:
Neuren Pharmaceuticals Ltd. (Australia) , Oxygen Biotherapeutics Inc. (United States) , Avanir Pharmaceuticals Inc. (United States)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation